EDMONTON, Alberta -- Broadly based MEMS manufacturer Micralyne Inc. and fabless bioMEMS specialist Microchips Inc. have agreed to collaborate on developing silicon-based MEMS for drug delivery applications. Under the agreement Micralyne will act as a manufacturing foundry for Microchips.
Edmonton-based Micralyne is a developer and manufacturer of MEMS for telecommunications, automotive and bio-analysis applications. Cambridge, Massachusetts-based Microchips works in the field of drug delivery systems, where it has a patented technology intended for the controlled administration of both protein and small-molecule drugs for use in pain management, hormone and steroid delivery, and some cancer and central nervous system disorders.
The two companies said they will work together as Microchips continues device development and proceeds towards clinical trials.
"We believe that the technology that MicroCHIPS is developing for implantable MEMS-based drug delivery has the potential to be an important step forward for the effective implementation of therapeutic regimens in the future", commented Chris Lumb, president and chief executive officer of Micralyne, in a statement. Lumb also said that drug delivery is a relatively new area of application for MEMS.
"It is a challenge to find a MEMS foundry having the experience of an OEM manufacturer and the willingness to work with a medical company during product development when volumes are low. Micralyne has the capability and experience to produce quality product at both low and high volumes," said John Santini, president and chief scientific officer of Microchips, in a statement.
Microchips was founded in 1999 by John Santini, Terry McGuire, and Massachusetts Institute of Technology professors Robert Langer and Michael Cima.